Systematic review / meta-analysis / 2019
Clinical studies link mushroom-derived lentinan to benefits during conventional cancer therapy.
A systematic review evaluated 135 clinical studies from China comprising 9,474 cancer treatment cases involving the shiitake polysaccharide lentinan. Most cases involved lung (3,469), gastric (3,039), or colorectal (1,646) malignancies. Across evaluated reports, lentinan use was linked to better quality of life and greater efficacy of concurrent chemotherapy or radiation treatment.
- Study type
- Systematic review of clinical studies
- Who was studied
- 9,474 cancer cases across 135 clinical studies, China
- What was measured
- Quality of life and cancer treatment efficacy
THE PAPER
Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China.
Zhang M, Zhang Y, Zhang L, Tian Q. Prog Mol Biol Transl Sci, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.